Sellas Life Sciences

SELLAS Life Sciences Announces Updated Positive Phase 2 Data Reinforcing Meaningful Clinical Benefit of its WT1 Immunotherapeutic Anti-cancer Treatment in Multiple Myeloma Patients

Data accepted for oral presentation at the 43rd annual meeting of the European Society for Blood and Marrow Transplantation – Results underscore ability of SELLAS’s lead product candidate, galinpepimut-S, to target a broad range of cancer indications – HAMILTON, Bermuda,...
Read More →

Advaxis and SELLAS Announce Licensing Agreement for Development of WT1 Antigen-Targeting Immunotherapy

PRINCETON, N.J., and HAMILTON, BERMUDA (Feb. 27, 2017) — Advaxis, Inc. (NASDAQ:ADXS) and SELLAS Life Sciences Group, both late-stage biopharmaceutical companies focused on developing cancer immunotherapies, today announced that Advaxis has granted SELLAS a license to...
Read More →